White blood cell counts as risk markers of developing metabolic syndrome and its components in the PREDIMED study.

Identifier:  PC:256

Handle: https://hdl.handle.net/20.500.11797/PC256

Authors:  Salas-Salvadó, J. for the PREDIMED Study Investigators.; Sorli, J.V.; Covas, M.I.; Serra-Majem, L.; Estruch, R.; Ortega-Calvo, M.; Salaverría, I.; Wärnberg, J.; Martínez-González, M.Á.; Bulló, M.; Ibarrola-Jurado, N.; Babio, N.

Abstract:
The Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities that includes hyperglucemia, hypertension, dyslipidemia and central obesity, conferring an increased risk of cardiovascular disease. The white blood cell (WBC) count has been proposed as a marker for predicting cardiovascular risk. However, few prospective studies have evaluated the relationship between WBC subtypes and risk of MetS. Participants were recruited from seven PREDIMED study centers. Both a baseline cross-sectional (n = 4,377) and a prospective assessment (n = 1,637) were performed. Participants with MetS at baseline were excluded from the longitudinal analysis. The median follow-up was 3.9 years. Anthropometric measurements, blood pressure, fasting glucose, lipid profile and WBC counts were assessed at baseline and yearly during the follow-up. Participants were categorized by baseline WBC and its subtype count quartiles. Adjusted logistic regression models were fitted to assess the risk of MetS and its components.